EUVIMEDEUVIMED entdecken
Crossref

Impact of dual-pathway inhibitor therapy on outcomes after femoropopliteal in-stent occlusion

Sho Nakao, Osamu Iida, Mitsuyoshi Takahara, Shin Okamoto, Takayuki Ishihara, Takuya Tsujimura, Yosuke Hata, Naoko Higashino, Toshiaki Mano

Cardiovascular Intervention and Therapeutics · 2026-07 · 41 (3) · 660-669

DOI: 10.1007/s12928-026-01255-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Intervention and Therapeutics, online erschienen am 03.03.2026. Verfasst von Sho Nakao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Kansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso, Amagasaki, 660-8511, Hyogo, Japan. shotwins0601@gmail.com. Hauptthemen laut MEDLINE: Popliteal Artery, Femoral Artery, Stents, Platelet Aggregation Inhibitors. Die Arbeit nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In-stent occlusions (ISO) in femoropopliteal lesions increase the risk of repeat occlusion after revascularization for ISO and worsen limb prognosis. This study investigated the impact of dual-pathway inhibitor therapy (DPIT) on clinical outcomes after femoropopliteal ISO revascularization. We retrospectively analyzed 120 limbs in 113 symptomatic patients who underwent EVT for femoropopliteal ISO between August 2012 and October 2021. After ISO revascularization, antithrombotic therapy was switched to DPIT in 39 limbs, whereas dual antiplatelet therapy (DAPT) was continued in 81 limbs. The primary endpoint was repeat ISO. Safety endpoints were major bleeding defined as Bleeding Academic Research Consortium (BARC) grade 3 or 5 bleeding and International Society on Thrombosis and Haemostasis (ISTH) major bleeding. Cox proportional hazards models were used to identify prognostic factors. To adjust for baseline imbalances, inverse probability of treatment weighting (IPTW)-weighted Cox model were performed. One-year freedom from repeat ISO was higher with DPIT than with DAPT (74.7 ± 7.9% vs. 49.1 ± 6.3%; p = 0.029). One-year freedom from BARC 3/5 bleeding (97.4% vs. 97.3%; p = 0.99) and ISTH major bleeding (87.8% vs. 90.2%; p = 0.83) were similar between the two groups. In multivariable analysis, DPIT was associated with lower repeat ISO risk (hazard ratio [HR] 0.41; p = 0.027), whereas chronic limb-threatening ischemia (HR 2.42; p = 0.016) and poor below-the-knee runoff (HR 3.38; p = 0.014) increased risk. In the IPTW-weighted Cox model, DPIT remained associated with reduced repeat ISO (HR 0.39, 95% CI 0.16-0.97; p = 0.043). Switching to DPIT after femoropopliteal ISO revascularization significantly reduced the risk of repeated ISO without increasing major bleeding events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Popliteal ArteryFemoral ArteryStentsPlatelet Aggregation InhibitorsPeripheral Arterial DiseaseEndovascular ProceduresDual Anti-Platelet TherapyHumansFemaleMaleRetrospective StudiesAgedTreatment OutcomeHemorrhage

Stichwörter der Autor:innen

Lower extremity arterial diseasedual pathway inhibitor therapyendovascular therapyfemoropopliteal segmentin-stent occlusion

Substanzen

Platelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Kansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso, Amagasaki, 660-8511, Hyogo, Japan. shotwins0601@gmail.com.
  • Cardiovascular Division, Osaka Police Hospital, Osaka, Japan.
  • Department of Diabetes Care Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
  • Kansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso, Amagasaki, 660-8511, Hyogo, Japan.

Zitieren

APA

Nakao, S., Iida, O., Takahara, M., Okamoto, S., Ishihara, T., Tsujimura, T., Hata, Y., Higashino, N., & Mano, T. (2026). Impact of dual-pathway inhibitor therapy on outcomes after femoropopliteal in-stent occlusion. Cardiovascular Intervention and Therapeutics, 41(3), 660-669. https://doi.org/10.1007/s12928-026-01255-5

Vancouver

Nakao S, Iida O, Takahara M, Okamoto S, Ishihara T, Tsujimura T, et al. Impact of dual-pathway inhibitor therapy on outcomes after femoropopliteal in-stent occlusion. Cardiovascular Intervention and Therapeutics. 2026;41(3):660-669. doi:10.1007/s12928-026-01255-5

BibTeX
@article{Nakao2026,
  author = {Nakao, Sho and Iida, Osamu and Takahara, Mitsuyoshi and Okamoto, Shin and Ishihara, Takayuki and Tsujimura, Takuya and Hata, Yosuke and Higashino, Naoko and Mano, Toshiaki},
  title = {Impact of dual-pathway inhibitor therapy on outcomes after femoropopliteal in-stent occlusion},
  journal = {Cardiovascular Intervention and Therapeutics},
  year = {2026},
  volume = {41},
  number = {3},
  pages = {660--669},
  doi = {10.1007/s12928-026-01255-5}
}
Kostenlos starten →